Shire launches Fosrenol

Shire has launched Fosrenol (lanthanum) for the treatment of hyperphosphataemia in chronic renal failure patients on haemodialysis, or continuous ambulatory peritoneal dialysis (CAPD).

Fosrenol inhibits the absorption of dietary phosphate by forming insoluble lanthanum phosphate complexes in the gastrointestinal tract. This leads to a reduction of serum phosphate levels.

Most patients can be managed with one tablet during each meal; patients who respond to lanthanum therapy usually achieve acceptable serum phosphate levels with 1500–3000mg daily.

Further information: Shire 01256 894000
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more